Sign In
Last checked at 
8 Nov 2018 07:00
Renalytix AI plc
("Renalytix" or the "Company")
Β
Director / PDMR shareholding
Β
Renalytix AI plc (AIM: RENX), a developer of artificial intelligence ("AI") enabled clinical diagnostic solutions for kidney disease, announces that it was yesterday notified that on 6 November 2018 the following PDMR undertook a transaction in the ordinary shares of 0.25 pence each in the capital of the Company ("Ordinary Shares"), at a price of 120 pence per Ordinary Share:
Β
Β | Β | Β | Β | Β Number of Ordinary Shares bought | Resultant Interest in Ordinary Shares | Resultant Interest in Ordinary Shares (%) | Β |
James McCullough | Chief Executive Officer | Β | Β | 16,150 |
2,870,110 | 5.33 | Β |
Β | Β | Β | Β | Β | Β | Β | Β |
Β | Β | Β | Β | Β | Β | Β | Β |
Β
NotificationΒ andΒ publicΒ disclosureΒ ofΒ transactionsΒ byΒ personsΒ dischargingΒ managerial responsibilitiesΒ andΒ personsΒ closelyΒ associatedΒ withΒ them
Β
1 Β | Details of the person discharging managerial responsibilities / person closely associated Β | ||||
a) Β | Name Β Β | James R. McCullough | |||
2 Β | Reason for the notification Β | ||||
a) Β | Position/status Β Β | Chief Executive Officer | |||
b) Β | Initial notification /Amendment Β Β | Initial Notification | |||
3 Β | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor Β | ||||
a) Β | Name Β Β | Renalytix AI plc | |||
b) Β | LEI Β Β | 213800NTOH3FK3WER551 | |||
4 Β | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted Β Β | ||||
a) Β | Description of the financial instrument, type of instrument | Ordinary shares of 0.25 pence each | |||
Β | Β | ||||
Identification code | GB00BYWL4Y04 | ||||
Β | Β | ||||
b) Β | Nature of the transaction Β Β | Purchase of Ordinary Shares | |||
c) Β | Price(s) and volume(s) | Β | Β | Β | Β |
Β | Β | Price(s) | Volume(s) | Β | |
Β | Β | 120 pence | 16,150 | Β | |
Β | Β | Β | Β | Β | |
d) Β | Aggregated information | n/a | |||
Β | Β | ||||
- Aggregated volume | Β | ||||
Β | Β | ||||
- Price | Β | ||||
Β | Β | ||||
e) Β | Date of the transaction Β Β | 06 November 2018 | |||
f) Β | Place of the transaction Β Β | London Stock Exchange | |||
Β
Β
For further information, please contact:
Β
Renalytix AI plcΒ | www.renalytixai.com | |
James McCullough, CEO | Via Walbrook PR or Tel: +1 646 397 3970 Β | |
Β | Β | |
N+1 Singer (Nominated Adviser & Broker) | Tel: 020 7496 3000 | |
Aubrey Powell / James White / George Tzimas (Corporate Finance)Tom Salvesen / Ross Penney (Corporate Broking) | Β | |
Β | Β | |
Β | Β | |
Β | Β | |
Walbrook PRΒ Limited | Tel: 020 7933 8780 orΒ renalytix@walbrookpr.com | |
Paul McManus / Lianne Cawthorne | Mob: 07980 541 893 / 07584 391 303 | |
| Β | Β | Β |
Β
Β
Β
Β
Follow the stocks
